Omeros (OMER) Income from Continuing Operations (2010 - 2026)
Omeros' (OMER) quarterly Income from Continuing Operations came in at 51249000.0 in Q1 2026, up 236.43% year-on-year from 15233295.76 in Q1 2025, and up 239.68% quarter-over-quarter from 36690000.0 in Q4 2025.
Omeros (OMER) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Omeros has disclosed Income from Continuing Operations across 17 years of filings, most recently posting 51249000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 51249000.0, up 236.43% year-over-year; the trailing twelve-month figure through Mar 2026 was 28990000.0 (up 83.34% YoY), and the FY2025 annual result was 4808000.0, up 97.37% from the prior year.
- Income from Continuing Operations came in at 51249000.0 for Q1 2026 at Omeros, up from 36690000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 51249000.0 in Q1 2026 to a low of 65125000.0 in Q2 2024.
- The 5-year median for Income from Continuing Operations is 39683000.0 (2023), against an average of 35762294.12.
- Across the five-year window, Income from Continuing Operations tumbled 141.34% in 2022 and jumped 236.43% in 2026, its largest moves.
- Omeros' Income from Continuing Operations stood at 46048000.0 in 2022, then grew by 5.75% to 43399000.0 in 2023, then climbed by 21.07% to 34255000.0 in 2024, then fell by 7.11% to 36690000.0 in 2025, then jumped by 239.68% to 51249000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 51249000.0 (Q1 2026), 36690000.0 (Q4 2025), and 12421000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Omeros | 737.87 Mn | 602.55 Mn | 9.31 Mn | 51.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 51.25 Mn |
| Dec 31, 2025 | -36.69 Mn |
| Sep 30, 2025 | -12.42 Mn |
| Jun 30, 2025 | -31.13 Mn |
| Mar 31, 2025 | -37.57 Mn |
| Dec 31, 2024 | -34.26 Mn |
| Sep 30, 2024 | -37.11 Mn |
| Jun 30, 2024 | -65.13 Mn |
| Mar 31, 2024 | -43.85 Mn |
| Dec 31, 2023 | -43.40 Mn |
| Sep 30, 2023 | -51.66 Mn |
| Jun 30, 2023 | -44.29 Mn |
| Mar 31, 2023 | -39.68 Mn |
| Dec 31, 2022 | -46.05 Mn |
| Sep 30, 2022 | -54.79 Mn |
| Jun 30, 2022 | -41.70 Mn |
| Mar 31, 2022 | -39.49 Mn |
| Dec 31, 2021 | -105.16 Mn |
| Sep 30, 2021 | -22.70 Mn |
| Jun 30, 2021 | -50.52 Mn |